LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.38 -4.83

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.34

Max

1.45

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+164.14% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-1.2M 173M
Eelmine avamishind	6.21
Eelmine sulgemishind	1.38

Uudiste sentiment

By Acuity

50%

168 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. märts 2026, 23:01 UTC

Tulu

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises - Update

5. märts 2026, 21:54 UTC

Tulu

Costco Posts Higher 2Q Profit on Rising Sales, Membership Fees

5. märts 2026, 21:35 UTC

Suurimad hinnamuutused turgudel

ServiceNow Shares Rise After CEO Says AI Can Add Value to Software

6. märts 2026, 00:00 UTC

Uudisväärsed sündmused

Its Missile Threat Degraded, Iran Is Taking Fewer Shots at More Targets -- WSJ

5. märts 2026, 23:46 UTC

Market Talk

Nikkei May Decline Amid Concerns About Energy Costs -- Market Talk

5. märts 2026, 23:33 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

5. märts 2026, 23:27 UTC

Market Talk

Middle East Fighting Will Prompt RBA to Delay Hike -- Market Talk

5. märts 2026, 22:54 UTC

Market Talk

Tulu

Costco Sold a $150,000 Diamond Ring in 2Q -- Market Talk

5. märts 2026, 22:50 UTC

Market Talk

Woodside Has More Exposure to Rising Gas Prices Than Santos -- Market Talk

5. märts 2026, 22:48 UTC

Tulu

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

5. märts 2026, 22:46 UTC

Tulu

Costco Evaluating Possibility of Tariff Refunds as 2Q Revenue Rises -- Update

5. märts 2026, 22:44 UTC

Tulu

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5. märts 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. märts 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. märts 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

5. märts 2026, 21:35 UTC

Tulu

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5. märts 2026, 21:32 UTC

Tulu

Costco Earnings Beat Expectations as Membership Model Shines -- Barrons.com

5. märts 2026, 21:26 UTC

Tulu

These Stocks Are Today's Movers: Broadcom, Trade Desk, Berkshire Hathaway, Rigetti, Corning, Ciena, Expedia, and More -- Barrons.com

5. märts 2026, 21:24 UTC

Tulu

Costco February Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 20.8% >COST

5. märts 2026, 21:23 UTC

Tulu

Costco February Same-Store Sales Ex-Changes in Gas and Foreign Exchange Rose 7% >COST

5. märts 2026, 21:22 UTC

Tulu

Costco 2Q Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5. märts 2026, 21:21 UTC

Tulu

Costco February Digitally-Enabled Sales Rose 21.8% >COST

5. märts 2026, 21:21 UTC

Tulu

Costco Total Co Comparable Sales for February Rose 7.9% >COST

5. märts 2026, 21:20 UTC

Tulu

Costco February Net Sales Were $21.69 B >COST

5. märts 2026, 21:20 UTC

Tulu

Marvell Earnings Beat Estimates on 'Robust' AI Demand. The Stock Jumps. -- Barrons.com

5. märts 2026, 21:20 UTC

Tulu

Costco Same-Store Sales Ex-Changes in Gas and Foreign Rose 6.7% >COST

5. märts 2026, 21:19 UTC

Tulu

Costco 2Q Digitally-Enabled Sales Ex-Changes in Gas and Foreign Exchange Rose 21.7% >COST

5. märts 2026, 21:18 UTC

Tulu

Costco 2Q Digitally-Enabled Sales Rose 22.6% >COST

5. märts 2026, 21:18 UTC

Tulu

Costco 2Q Same-Store Sales Up 7.4% >COST

5. märts 2026, 21:15 UTC

Tulu

Costco 2Q EPS $4.58 >COST

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

164.14% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 164.14%

Kõrge 7 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

168 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.